Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Trial Profile

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms IMPACT
  • Most Recent Events

    • 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 29 Oct 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Aug 2018 to 1 Nov 2018.
    • 11 Sep 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top